Custom In Vivo Tumor Model Services

Online Inquiry

Name *

Email *

Phone *

Services Interested *

Project Description

Please note that we are not a pharmacy or clinic, so we are unable to see patients and do not offer diagnostic and treatment services for individuals.

Custom In Vivo Tumor Model Services

Preclinical in vivo tumor model services and oncology research - Alfa Cytology

In Vivo Tumor Models represent a sophisticated preclinical evaluation system, established by grafting or inducing tumors within animal hosts, that faithfully recapitulates the complex tumor microenvironment, systemic drug metabolism, and physiological interactions of human malignancies. Alfa Cytology provides end-to-end, fully customized in vivo model development services, enabling researchers and drug developers to leverage these highly translatable platforms for advanced oncology research, pharmacokinetic assessment, and therapeutic validation.

Overview of In Vivo Tumor Models

In vivo tumor models serve as the cornerstone of preclinical oncology research. Unlike in vitro cultures, these systems replicate the complex biological environment where tumors grow, interact with the host’s immune and vascular systems, and respond to systemic drug exposure.

As the landscape of cancer treatment shifts toward precision medicine and immuno-oncology, the choice of model—from traditional Cell Line-derived Xenografts (CDX) to sophisticated Patient-derived Xenografts (PDX) and humanized systems—is critical in predicting clinical efficacy and understanding drug mechanisms.

Applications & Research Advancements

At Alfa Cytology, we bridge the gap between standard assays and cutting-edge oncology research. Our in vivo platforms are optimized to address the most critical challenges in modern drug discovery:

Immuno-Oncology & Humanization

Validated Humanized Platforms (HSC/PBMC/BLT): We provide specialized systems to evaluate CAR-T, BiTEs, and checkpoint inhibitors within a functional human immune context, supported by longitudinal flow cytometry data.

Translational Medicine & PDX

Leveraging Patient-Derived Xenografts (PDX) to maintain genetic heterogeneity, enabling precise "mouse clinical trials" and the identification of clinical-grade predictive biomarkers.

Orthotopic & Metastasis Modeling

Shifting toward organ-specific (orthotopic) implantation to faithfully capture tumor microenvironment (TME) interactions and systemic disease progression for advanced-stage drug assessment.

Target Validation & Resistance

Employing gene-edited models (e.g., Ba/F3 mutant lines) and acquired resistance systems to resolve drug-target interactions and validate next-generation inhibitors or combination therapies.

Our Services

To meet the diverse needs of global drug developers, Alfa Cytology offers an extensive selection of validated in vivo tumor models. From high-throughput screening platforms to sophisticated patient-mimicking systems, our portfolio provides the physiological depth required to de-risk your clinical candidates.

Comprehensive In Vivo Model Portfolio

High-throughput and cost-effective platforms for rapid drug screening.

CDX mouse model for preclinical drug efficacy screening

Cell Line-derived Xenograft (CDX) Models

Mouse CDX Models: Improved humanized versions are available for evaluating immune responses induced by PD-1/PD-L1 blockers (e.g., BMS202).
Rat CDX Models: Utilizing SCID or nude rats for robust PK/PD assessments and integrated in vitro-in vivo validation.
Ba/F3 Xenograft Models: Engineered lines (e.g., ALK or BCR-ABL mutations) for target validation and studying resistance in small-molecule kinase inhibitors.

Patient-Derived Xenograft (PDX) Models

Preserve genomic landscape, heterogeneity, and drug sensitivity of original patient tumors.

Ideal for biomarker discovery, co-clinical trials, and personalized medicine.

PDX model preserving patient tumor heterogeneity for translational research

Orthotopic tumor models implanted into organ of origin to simulate native microenvironment and metastasis

Orthotopic Models

Site-specific implantation to recapitulate native tumor microenvironment and metastatic behavior.

Implantation into organ of origin.

Better predicts clinical response by incorporating organ‑specific stroma and signaling.

Immuno-Oncology Platforms

Syngeneic Models: Utilizing immunocompetent mice to evaluate therapies that require a fully functional immune system, such as checkpoint inhibitors and CAR-T.
Humanized Mouse Models: Reconstituting human immunity in mice to test human-specific biologics and bispecific antibodies.

Syngeneic and humanized mouse models for immuno-oncology drug evaluation

Advanced disease models for metastasis and acquired drug resistance

Advanced Disease & Resistance Models

Metastatic Models: Spontaneous and experimental metastasis models (lung, brain, etc.) to assess drug efficacy in advanced disease stages.
Drug Resistance Model: Specifically developed models (e.g., HCC827-ER1) to study acquired resistance to EGFR inhibitors and evaluate combination strategies.

Induced Tumor Models

Chemically induced models (e.g., DEN-induced hepatocellular carcinoma) that mirror the natural progression of cancer from healthy tissue.

Metastasis and drug resistance models

Service Workflow for In Vivo Tumor Evaluation

Consultation & Study Design

Our experts collaborate with you to select the optimal model and customize a protocol, including dosing regimens, group sizes, and specific clinical endpoints.

Model Preparation & Initiation

We manage animal procurement, cell/tissue expansion, and precise tumor implantation, ensuring synchronized group enrollment and baseline consistency.

Study Execution & Monitoring

Conducted under strict AAALAC guidelines with daily clinical observation and routine tumor measurements, supported by regular progress reports and real-time data updates.

Data Analysis & Reporting

Upon completion, we deliver a comprehensive, IND-ready report featuring statistical analysis, histopathology, and all documentation required for regulatory filings.

Why Choose Alfa Cytology?

In vitro ADME assay for evaluating drug absorption properties.

Tailored In Vivo Development

Delivering customized model development with optimized implantation protocols for specific cancer indications and unique therapeutic research objectives.

In vitro ADME analysis for drug distribution and clearance.

High Standards of Animal Welfare

Operating in full compliance with AAALAC guidelines and the 3Rs principles, ensuring high-quality, ethically-sound data through rigorous veterinary care and protocol oversight.

Laboratory metabolism study using in vitro ADME testing.

Integrated Preclinical Solutions

Offering a seamless pipeline from model generation and drug administration to comprehensive downstream PK/PD, histopathology, and biomarker analysis.

Drug permeability and excretion assessment in an in vitro ADME study.

Validated Model Repository

Accelerating timelines with immediate access to a vast biobank of validated CDX, Syngeneic, and PDX models across a broad spectrum of oncological targets.

Contact Us

Alfa Cytology's integrated in vivo tumor model development and research services provide a robust, translatable platform to transform your oncology research and preclinical development programs. From specialized model generation to customized pharmacodynamic studies, we partner with you to generate reliable, clinically relevant data. Contact us today to consult with our oncology experts. Request our full biobank catalog or a customized study design for your PK/PD and efficacy evaluation.

For research use only. Not intended for any clinical use.